<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Indium In-111 capromab pendetide: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Indium In-111 capromab pendetide: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Indium In-111 capromab pendetide: Drug information</div><div class="clear"></div><div id="topicText">For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F23449459"><span class="drugH1">Brand Names: US</span>
<ul>
<li>ProstaScint [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F23449462"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Radiopharmaceutical</li></ul></div>
<div class="block doa drugH1Div" id="F23450128"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a242dd7a-63e5-444d-b313-c1b0fb21c573">Diagnostic imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diagnostic imaging: </b>IV: 0.5 mg radiolabeled with 5 mCi of Indium 111 chloride. May be readministered if infiltration or a technically inadequate scan occurs.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990531"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F50987849"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doe drugH1Div" id="F58348289"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F23610018"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Immunologic: Antibody development (HAMA; single infusion: &gt;8 ng/mL 8%; &gt;100 ng/mL 1%; repeat infusion: 19%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (1%), hypotension (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum bilirubin (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Burning sensation (thigh), dysgeusia, dyspnea, fever, headache, increased liver enzymes, injection site reaction, myalgia, pruritus, skin rash, weakness</p></div>
<div class="block coi drugH1Div" id="F23449468"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to Indium 111 capromab pendetide, other products of murine origin,  Indium  In 111 chloride, or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F23449469"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Allergic reactions, including anaphylaxis, can occur in patients who receive murine antibodies. Medications for the treatment of hypersensitivity reactions should be available for immediate use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Human antimurine antibodies (HAMA): Treatment may result in the development of HAMA; increased adverse reactions, interference with murine-antibody based immunoassays, and compromised efficacy of murine antibody-based agents may occur. Patients should be informed to discuss prior use of murine-antibody based products and that the use of this agent may hinder the ability for future use of murine-based products, to diagnose recurrence of tumor, or perform some other laboratory tests.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special handling: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use only under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority. <b>Note:</b> Contents of kit are not radioactive; however, adequate shielding is required after addition of radioactive material.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other Warnings/Precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Not intended to be used as a screening tool for prostate cancer. Should not be readministered to assess response to treatment. Due to the high rate of false positive or false negative imagine interpretations, other appropriate tests should be done for confirmation of results. Do use this in replace of a bone scan for evaluation of skeletal metastases. Prior to each 72 to 120 hour imaging session, patients should receive a cathartic the evening before and a cleansing enema within an hour before the test; the patient’s bladder should also be catheterized and irrigated.</p></div>
<div class="block dosfc drugH1Div" id="F23613301"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">ProstaScint may contain a significant amount of sodium.</p></div>
<div class="block foc drugH1Div" id="F23463063"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ProstaScint: Capromab pendetide 0.5 mg per vial [to be combined with Indium In 111 (not included)] [DSC] [pyrogen free; contains mouse (murine) and/or hamster protein]</p></div>
<div class="block geq drugH1Div" id="F23449461"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block adm drugH1Div" id="F23450137"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: For IV administration. Administer over 5 minutes. Do not mix with any other medications. Administer a cathartic the evening before the imaging and a cleansing enema within 1 hour prior to each 72- to 120-hour imaging session. The bladder should also be catheterized and irrigated. The first imaging session should be done approximately 30 minutes following the infusion. The second imaging session should be done 72 to 120 hours after the infusion. Refer to manufacturer’s prescribing information for additional imaging information.</p>
<p style="text-indent:-2em;margin-left:2em;">Radiopharmaceutical; use appropriate precautions for handling and disposal.</p></div>
<div class="block use drugH1Div" id="F23449465"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Diagnostic imaging: </b>Diagnostic imaging agent indicated in patients newly diagnosed with biopsy-proven prostate cancer (clinically localized after standard diagnostic evaluation) who are at high risk for pelvic lymph node metastases and in patients postprostatectomy with a rising PSA and negative standard metastatic evaluation, but a high clinical suspicion of metastatic disease</p></div>
<div class="block mst drugH1Div" id="F23449458"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F23693088"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F23693085"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Antiandrogens: May diminish the diagnostic effect of Indium 111 Capromab Pendetide.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antigonadotropic Agents: May diminish the diagnostic effect of Indium 111 Capromab Pendetide.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May diminish the diagnostic effect of Indium 111 Capromab Pendetide.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen Derivatives: May diminish the diagnostic effect of Indium 111 Capromab Pendetide.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Luteinizing Hormone-Releasing Hormone Analogs: May diminish the diagnostic effect of Indium 111 Capromab Pendetide.<i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F23449466"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproductive studies have not been conducted. Not recommended for use in women.</p></div>
<div class="block brc drugH1Div" id="F23449467"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">Not indicated for use in women.</p></div>
<div class="block pha drugH1Div" id="F23449474"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Capromab pendetide is a murine IgG1 kappa monoclonal antibody that is directed against the glycoprotein Prostate Specific Membrane Antigen (PSMA), which is expressed by prostate epithelium. </p></div>
<div class="block phk drugH1Div" id="F23449476"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: ~2 to 6 L</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Decays by electron capture</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Physical: 67.2 hours; Terminal: ~56 to 78 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (10% over 72 hours)</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Prostascint Kit [prescribing information]. Langhorne, PA: EUSA Pharma; June 2012.</div>
</li></ol></div><div id="topicVersionRevision">Topic 93420 Version 45.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
